Cephalon alliance
In December 2010, Mesoblast formed a strategic alliance with global biopharmaceutical company, Cephalon Inc., to develop and commercialize its novel adult stem cell therapeutics for degenerative conditions of the cardiovascular and central nervous systems. These conditions include congestive heart failure and acute myocardial infarction, stroke, Parkinson’s disease and Alzheimer’s disease, The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.
Cephalon is funding all late stage clinical development costs worldwide for the specific products, as well as all sales and marketing costs.
Mesoblast retains all manufacturing rights and will sell finished products to Cephalon on a transfer price basis.
Cephalon has acquired a 19.9% stake in Mesoblast.
Other indications
Mesoblast intends to bring other products to market either on its own or together with additional strategic partners.
These products include:
- diabetes
- autoimmune and inflammatory diseases
- ophthalmic indications
- orthopedic cartilage and bone conditions.